Bacterial Infections
Conditions
Keywords
Dalbavancine, Xydalba
Brief summary
This observational study will collect data on the use of the drug Xydalba® in daily clinical practice in Germany. Such observational studies are also referred to as registries. The sponsor of the study is Correvio International Sárl, based in Switzerland. Xydalba® contains the active substance dalbavancin, a remedy for a certain type of bacterial pathogens (so-called gram positive bacteria) which cause the disease. Active ingredients against bacteria are also called antibiotics. Correvio wants to know which patients received the drug and how the disease went. The treatment places where you got Xydalba, ie clinic, intensive care unit or elsewhere should be recorded. In addition, it is important in this type of medication to track whether the pathogens are changing in any way. Any safety-relevant events (such as side effects) that have occurred during treatment should be investigated by the sponsor and submitted to the competent European authorities.
Detailed description
OBJECTIVES The objectives of this registry are as follows: * To determine the following characteristics in patients who received intravenous Xydalba administration: * Patient characteristics. * Disease characteristics. * Pathogen characteristics. * To characterize the usage of Xydalba. * To characterize the patient's residence and, in hospitalized patients, the lengths of hospital and intensive care unit (ICU) stays, and the destination upon hospital discharge. * To assess the response of Xydalba treatment, based on clinician determination. * To characterize the major healthcare resource utilization (HRU) of patients treated with Xydalba. REGISTRY DESIGN This is a multicenter, prospective and retrospective registry of adult patients treated with Xydalba in Germany. All Adverse events (AEs) (serious and non-serious; special situations; related and not-related, collected prospectively or retrospectively) will be recorded in the eCRF. Treatment related AEs and SAEs will be reported to the healthcare authorities, as requested by local regulations and according to current Guideline on good pharmacovigilance practices (GVP) Module VI - Collection, management and submission of reports of suspected adverse reactions to medicinal products (Rev 2). TEST PRODUCT (S), DOSE, AND MODE OF ADMINISTRATION Xydalba (dalbavancin) as prescribed by the physician according to clinical practice. RATIONALE This prospective and retrospective registry is designed to capture information about the clinical use of Xydalba, its safety and effectiveness, characteristics of the patient, disease, pathogen, clinical course, treatment course, and hospitalization. This registry will capture the data in real world setting on patients who received Xydalba.
Interventions
DRUGXydalba
Information will be recorded about Xydalba administration (e.g. dose(s), number of infusions, length of infusions, dates or schedule of administration, sites of administration \[e.g. hospital, ICU\]), and reason for discontinuation, including response to treatment to assess whether the patient was clinically improving when Xydalba was discontinued
Sponsors
AMS Advanced Medical Services GmbH
PrimeVigilance
Correvio International Sarl
Study design
Observational model
COHORT
Time perspective
OTHER
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
A patient must meet all of the following criteria to be eligible for participation in the study. 1. Male and female patient, ≥18 years of age at the time of receipt of Xydalba. 2. The patient received at least one infusion of Xydalba. 3. Patient signed the consent form
Exclusion criteria
A patient who meets the following criterion is not eligible for participation in the study. 1\. The patient was enrolled in a clinical trial in which treatment for Xydalba is managed through a protocol.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Prevalence of ABSSSI and other primary diagnoses among patients who received Xydalba (dalbavancin) as treatment for this primary diagnosis | Day of first dose |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Clinical response | at 30 days after first dose | Clinical response by cured, improved, failure, non-evaluable, worsening or other (non-clinically evaluable) |
| Clinical response by diagnosis | at 30 days after first dose | Clinical response by diagnosis (ABSSSI, Gram-positive bacteremia, other associated diagnosis) |
| Time from Xydalba treatment onset to clinical response | up to 30 days after first dose | — |
| Adverse Events, Adverse Drug Reactions and Special Situations | up to 30 days after first dose | — |
Other
| Measure | Time frame | Description |
|---|---|---|
| Percentage first-line vs. subsequent-line monotherapy | up to 30 days after first dose | % of cases for which Xydalba is given as first-line and % of cases for which Xydalba is given as subsequent-line |
| Length of Xydalba Infusions | up to 30 days after first dose | length of Infusions in minutes |
| Reason for discontinuation | up to 30 days after first dose | descriptive listing of type of reasons |
| Prior Antibiotic Therapies | from the time of the primary specified infectious disease diagnosis until Xydalba treatment (estimated to be within 3 months of Xydalba treatment) | Descriptive summary of other antibiotic therapies received |
| Xydalba Treatment dose(s) | up to 30 days after first dose | Dose(s) of Xydalba in mg per infusion |
| Number of Xydalba Infusions | up to 30 days after first dose | number of Infusions given |
| Days of Xydalba treatment | up to 30 days after first dose | number of Days of treatment |
| Percentage of monotherapy vs. concurrent therapy | up to 30 days after first dose | % of cases for which Xydalba is given as monotherapy and % of cases for which Xydalba is given as concurrent therapy |
Countries
Germany
Outcome results
None listed